What you should know:
1. Fourteen scientific papers support DSG’s effectiveness.
2. SpineGuard CEO and Co-founder Stéphane Bette said, “This milestone is the perfect confirmation of the reliability and the clinical value of our DSG technology, its ability to secure the placement of implants in the skeleton and the spine in particular.”
3. Ms. Bette said SpineGuard recently became EBITDA breakeven. SpineGuard will continue to support DSG as it attempts to further its robotic surgery integration.
More articles on devices:
Midwest Orthopaedic at Rush opens physical therapy clinic — 3 insights
Total Orthopedics and Sports Medicine opens $3M facility — 3 insights
Middlesex Health opens orthopedic-focused OR — 4 insights
